CLEW receives FDA Emergency Use Authorization (EUA)
‘Clinical intelligence’ company, CLEW, has announced that its COVID-19 predictive screening tool for use in intensive care units has been awarded an emergency use authorization by the US Food and Drug Administration (FDA).
The platform uses artificial intelligence to help medical teams identify which patients have a greater chance of respiratory failure or hemodynamic instability.
“Healthcare providers need more than simple analytics,” said Gal Salomon, CLEW’s CEO. “Systems need to integrate into the provider’s workflow, offering ease of use and actionable data. The CLEWICU platform is designed to enable healthcare providers to monitor patient predicted risk levels across all units in real-time, allowing for smart decision making about clinical resource allocation, and ensuring prompt, proactive and efficient patient care.”